Cargando…

Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]

Detalles Bibliográficos
Autores principales:	Runfeng, Li, Yunlong, Hou, Jicheng, Huang, Weiqi, Pan, Qinhai, Ma, Yongxia, Shi, Chufang, Li, Jin, Zhao, Zhenhua, Jia, Haiming, Jiang, Kui, Zheng, Shuxiang, Huang, Jun, Dai, Xiaobo, Li, Xiaotao, Hou, Lin, Wang, Nanshan, Zhong, Zifeng, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603740/ https://www.ncbi.nlm.nih.gov/pubmed/34802883 http://dx.doi.org/10.1016/j.phrs.2021.105907

Ejemplares similares

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
por: Runfeng, Li, et al.
Publicado: (2020)

Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
por: Ma, Qinhai, et al.
Publicado: (2020)

Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway
por: Ma, Qinhai, et al.
Publicado: (2020)

The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function
por: Ding, Yuewen, et al.
Publicado: (2017)

Corrigendum to “Traditional Chinese medicine for COVID-19 treatment” [Pharmacol. Res. 155 (2020) 104743]
por: Ren, Jun-ling, et al.
Publicado: (2020)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

Patient-derived avian influenza A (H5N6) virus is highly pathogenic in mice but can be effectively treated by anti-influenza polyclonal antibodies
por: Pan, Weiqi, et al.
Publicado: (2018)

Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402]
por: Di Maria, Emilio, et al.
Publicado: (2021)

Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation
por: Hua, Chen, et al.
Publicado: (2021)

Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19
por: Liu, Lei, et al.
Publicado: (2021)

Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
por: Shen, Pan, et al.
Publicado: (2021)

A new perspective to improve the treatment of Lianhuaqingwen on COVID-19 and prevent the environmental health risk of medication
por: Gu, Wenwen, et al.
Publicado: (2022)

Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates
por: Ma, Qinhai, et al.
Publicado: (2022)

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial
por: Hu, Ke, et al.
Publicado: (2021)

Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening
por: Chen, Xiaofei, et al.
Publicado: (2021)

Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic
por: Liang, Chengyuan, et al.
Publicado: (2021)

Active immunization with Pseudomonas aeruginosa vaccine protects mice from secondary Pseudomonas aeruginosa challenge post-influenza virus infection
por: Wu, Xiaofeng, et al.
Publicado: (2023)

Gene silencing of β-galactosamide α-2,6-sialyltransferase 1 inhibits human influenza virus infection of airway epithelial cells
por: Wu, Dong, et al.
Publicado: (2014)

Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial
por: Gong, Xiaowei, et al.
Publicado: (2021)

Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials
por: Fan, Zheng, et al.
Publicado: (2021)

Effect of Lianhuaqingwen Capsules on Airway Inflammation in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
por: Dong, Liang, et al.
Publicado: (2014)

Corrigendum to “Ginsenoside Ro, an oleanolic saponin of Panax ginseng, exerts anti-inflammatory effect by direct inhibiting toll like receptor 4 signaling pathway” [J Ginseng Res 46 (2022) 156–166]
por: Xu, Hong-Lin, et al.
Publicado: (2022)

Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study
por: Fang, Jie, et al.
Publicado: (2020)

Effect of Jinzhen granule on two coronaviruses: The novel SARS-CoV-2 and the HCoV-229E and the evidences for their mechanisms of action
por: Ma, Qinhai, et al.
Publicado: (2022)

Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: A systematic review and meta-analysis
por: Liu, Ming, et al.
Publicado: (2021)

The antiviral activity of arbidol hydrochloride against herpes simplex virus type II (HSV-2) in a mouse model of vaginitis
por: Du, Qiuling, et al.
Publicado: (2019)

Broad antiviral and anti-inflammatory activity of Qingwenjiere mixture against SARS-CoV-2 and other human coronavirus infections
por: Xie, Peifang, et al.
Publicado: (2021)

A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants
por: Dong, Yidan, et al.
Publicado: (2022)

Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule
por: Lan, Xiao-fang, et al.
Publicado: (2021)

Corrigendum to “Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost” [Biochem. Pharmacol. 178 (2020) 114057]
por: Mohammed El Tabaa, Manar, et al.
Publicado: (2020)

The clinical efficacy and safety research of Lianhuaqingwen (LHQW) in treatment of COVID-19: A systematic review and meta-analysis
por: Fang, Ling, et al.
Publicado: (2022)

Association between IRGM polymorphisms and tuberculosis risk: A meta-analysis
por: Xie, Haojun, et al.
Publicado: (2017)

Extension of experiment T 156
por: CERN. Geneva. Track Chamber Committee
Publicado: (1968)

Clinical analysis of 156 cases of multiple organ failure caused by fish bile
por: Yuan, Fa-huan, et al.
Publicado: (2015)

A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine
por: Leong, F. Joel, et al.
Publicado: (2018)

Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial
por: Zheng, Jin-ping, et al.
Publicado: (2023)

Systematic Review With Meta-analysis: Prompt Endoscopy As the Initial Management Strategy for Uninvestigated Dyspepsia in Asia: (Aliment Pharmacol Ther 2015;41:239–252)
por: Jung, Hye-Kyung
Publicado: (2015)

Erratum for factors associated with visceral fat accumulation in the general population in Okinawa, Japan (World J Gastrointest Pharmacol Ther 2016; 7: 261-267)
por: Arakaki, Shingo, et al.
Publicado: (2018)

Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment
por: Li, Zhengtu, et al.
Publicado: (2016)

A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19
por: Zhang, Xiaobo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jh53pm61oo14gh33nr1qcq7k8a